Stockreport

Vincerx Pharma Reports Third Quarter 2024 Financial Results

Vincerx Pharma, Inc.  (VINC) 
PDF Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by ea [Read more]